series-b
Stage
3
Investors
About
Neurogastrx is a privately held, clinical-stage biopharmaceutical company developing therapies for serious gastrointestinal diseases. Its lead program, NG101, is an oral, peripherally acting dopamine D2 receptor antagonist being studied for gastroparesis and nausea/vomiting associated with GLP-1 agonists.
Explore Neurogastrx, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.